Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study

European Heart Journal

Volumn 19, Issue 10, 1998, Pages 1552-1563

  Vantrimpont, P ^a   Rouleau, Jean L ^a   Ciampi, A ^a   Harel, F ^a   De Champlain, J ^b   Bichet, D ^b   Moye L A ^c   Pfeffer, M ^d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d Montreal Heart Institute ^*

Author keywords

Neurohormones; Post infarction; Prognosis; Survival

Indexed keywords

ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; NEUROHORMONE; NORADRENALIN; RENIN;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TIME;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NOREPINEPHRINE; PROGNOSIS; PROSPECTIVE STUDIES; RENIN; SURVIVAL RATE;

EID: 0032188859     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1093     Document Type: Article

References (21)

1. [1] Rouleau JL, Moyé LA, de Chaplain J, Klein M, Packer M, Dagenais G. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991; 68: 80D-6D.
2. [2] Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390-8.
3. [3] Remes J. Neuroendocrine activation after myocardial infarction. Br Heart J 1994; 72 (Suppl): 65-9.
4. [4] Omland T, Aakvaag A, Bonarjee VVS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-9.
5. [5] Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
6. [6] Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma natriuretic factor, norepinephrine and epinephrine in acute myocardial infarction. Am J Cardiol 1993; 72: 255-9.
7. [7] Omland T, Nonarjee VVS, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 1995; 76: 230-5.
8. [8] Hall C, Cannon CP, Forman S, Braunwald E for the TIMI II Investigators. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. J Am Coll Cardiol 1995; 26: 1452-6.
9. [9] Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91.
10. [10] Hall C, Rouleau JL, Moyé L et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
11. [11] Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
12. [12] Benedict CR, Shelton B, Johnstone DE et al. for the SOLVD Investigators. Prognostic significance of plasma norepine-phrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-7.
13. [13] Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13: 1534-9.
14. [14] Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, Group ftCTS. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-6.
15. [15] Rockman HA, Juneau C, Chatterjee K, Rouleau JL. Predictors of sudden and low output death in chronic congestive heart failure: importance of plasma renin activity. Am J Cardiol 1989; 64: 1343-8.
16. [16] Moyé LA, Pfeffer MA, Braunwald E. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol 1991; 68: 70D-9D.
17. [17] Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction. N Engl J Med 1992; 327: 669-77.
18. [18] Mettauer B, Rouleau JL, Bichet D et al. Differential long-term intrarenal and neurohumoral effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Circulation 1986; 73: 1724-9.
19. [19] Wilson N, Ledsome JR, Keeler R, Rankin AJ, Wade JP, Cournyea CA. Heterologous radioimmunoassay of atrial natriuretic peptide in dog and rabbit plasma. J Immunoassay 1986; 7: 73-96.
20. [20] Rouleau JL, Kortas C, Bichet D, de Champlain J. Neurohumoral and hemodynamic changes in congestive heart failure: lack of correlation and evidence of compensatory mechanisms. Am Heart J 1988; 116: 746-57.
21. [21] Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.